Sakai K, Yayoi E, Terasawa T, Koyama H, Takatsuka Y, Inoue K, Tominaga T, Yoshida K, Kurokawa Y, Watanabe H
Gan To Kagaku Ryoho. 1983 Nov;10(11):2301-8.
In 37 cases of locally advanced breast cancer, arterial administration of adriamycin (ADR), given a total dose of 150 mg in a single dose of 30 mg or 50 mg, was attempted as means of preoperative chemotherapy, and its tumor contraction action in the primary breast cancer and side effects were studied. On the basis of the "Assessement Criteria of Therapeutic Effects on Advanced and Recurrent Breast Cancer" by the Japan Breast Cancer Society, complete response (CR) was noted in 3 cases, and partial response (PR) in 25 cases, with an efficacy rate (CR+PR) of 75.7% (28/37 cases). There was no significant difference in the efficacy rate between the two groups and histological effects were statistically similar. Besides, regarding the difference in the route of administration, the clinical effects were more significant in the group administered from two routes of subclavian artery and internal thoracic artery than in the group injected only from the the subclavian artery. As for side effects, alopecia, leukocytopenia, anorexia, nausea and vomiting were found at high frequencies, and local toxicity was also recognized at a considerable rate, but there was no difference between single dose groups, and these adverse effects were considered to be permissible as far as the total dose up to 150 mg.
在37例局部晚期乳腺癌患者中，尝试采用动脉注射阿霉素（ADR）作为术前化疗手段，单次剂量为30mg或50mg，总剂量为150mg，研究其对原发性乳腺癌的肿瘤缩小作用及副作用。根据日本乳腺癌学会的“晚期及复发性乳腺癌治疗效果评估标准”，3例达到完全缓解（CR），25例达到部分缓解（PR），有效率（CR + PR）为75.7%（28/37例）。两组的有效率无显著差异，组织学效果在统计学上相似。此外，关于给药途径的差异，经锁骨下动脉和胸廓内动脉两条途径给药的组比仅经锁骨下动脉注射的组临床效果更显著。至于副作用，脱发、白细胞减少、厌食、恶心和呕吐的发生率较高，局部毒性也有相当比例，但单剂量组之间无差异，并且认为在总剂量达150mg的情况下这些不良反应是可以接受的。
